A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 132 participants.

Also called NCT04596631

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 132 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04596631
  • EudraCT 2018-002952-34
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Austria, Belgium, Czechia, Greece, India, Israel, Lebanon, Malaysia, Mexico, Morocco, Netherlands, New Zealand, North Macedonia, Portugal, Puerto Rico, Romania, Russia, Taiwan, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04596631. Randomized; quadruple masking; primary purpose treatment. Start 2020-11-02 (actual); primary completion 2025-04-29 (actual). Results posted on 2026-08-21.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes
Acronym
PIONEER TEENS
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Oral semaglutide
Intervention (Drug)
Placebo (semaglutide)
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct04596631
Content hash
23035404ff77489e886fbd1186dcbe2892f2b65177fc76ad007bba8790310522